ROYALTY PHARMA PLC

(RPRX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Royalty Pharma to Announce Fourth-Quarter and Full-Year 2021 Financial Results on February 15, 2022

01/20/2022 | 07:45am EDT

NEW YORK, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth-quarter and full-year 2021 financial results on Tuesday, February 15, 2022 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.

Conference Call Information

The conference call can be accessed live over the phone for U.S. callers by dialing (833) 519-1253 or for international callers by dialing +1 (914) 800-3826. The passcode to access the conference call is 6819125.

A live webcast may be accessed from the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/news-and-events/events. A replay of the conference call and webcast will be archived on the company's website for at least 30 days.

About Royalty Pharma

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 40 commercial products, including AbbVie and Johnson & Johnson’s Imbruvica, Johnson & Johnson’s Tremfya, Astellas’ and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s Trodelvy, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates. For more information, visit www.royaltypharma.com.

Royalty Pharma Investor Relations and Communications

+1 (212) 883-6772
ir@royaltypharma.com


Primary Logo

Source: RP Management, LLC

2022 GlobeNewswire, Inc., source Press Releases

All news about ROYALTY PHARMA PLC
05/18Royalty Pharma Investor Day Highlights Stronger Growth Outlook and the Power of Its Uni..
AQ
05/17Royalty pharma announces charitable alliance with mount sinai
AQ
05/17TRANSCRIPT : Royalty Pharma plc - Analyst/Investor Day
CI
05/17Royalty Pharma Sets New Capital Deployment Target
MT
05/17ROYALTY PHARMA PLC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K..
AQ
05/17Royalty Pharma Investor Day Highlights Stronger Growth Outlook and the Power of Its Uni..
GL
05/17Royalty Pharma Investor Day Highlights Stronger Growth Outlook and the Power of Its Uni..
AQ
05/13Scotiabank Initiates Royalty Pharma at Outperform with $53 Price Target
MT
05/11ROYALTY PHARMA PLC : Other Events (form 8-K)
AQ
05/05ROYALTY PHARMA PLC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RES..
AQ
More news
Analyst Recommendations on ROYALTY PHARMA PLC
More recommendations
Financials (USD)
Sales 2022 2 276 M - -
Net income 2022 847 M - -
Net Debt 2022 5 653 M - -
P/E ratio 2022 19,4x
Yield 2022 1,87%
Capitalization 17 204 M 17 204 M -
EV / Sales 2022 10,0x
EV / Sales 2023 9,59x
Nbr of Employees -
Free-Float 47,2%
Chart ROYALTY PHARMA PLC
Duration : Period :
Royalty Pharma plc Technical Analysis Chart | RPRX | GB00BMVP7Y09 | MarketScreener
Technical analysis trends ROYALTY PHARMA PLC
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 39,52 $
Average target price 52,50 $
Spread / Average Target 32,8%
EPS Revisions
Managers and Directors
Pablo Gerardo Legorreta Chairman & Chief Executive Officer
Terrance Patrick Coyne Chief Financial Officer & Executive Vice President
James F. Reddoch Chief Scientific Officer & Executive VP
Marshall Urist Executive Vice President-Research & Investments
Sara Klymkowsky Vice President-Research & Investments
Sector and Competitors
1st jan.Capi. (M$)
ROYALTY PHARMA PLC-0.83%17 204
JOHNSON & JOHNSON3.45%465 705
PFIZER, INC.-11.14%294 404
ELI LILLY AND COMPANY8.19%269 013
ABBVIE INC.11.53%266 851
ROCHE HOLDING AG-15.67%266 707